This company listing is no longer active
GNBT Stock Overview
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Generex Biotechnology Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$0.32 |
| 52 Week Low | US$0.0001 |
| Beta | -1.69 |
| 11 Month Change | -77.27% |
| 3 Month Change | 0% |
| 1 Year Change | -99.79% |
| 33 Year Change | -99.96% |
| 5 Year Change | -99.56% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| GNBT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -73.7% | -3.0% | -2.9% |
| 1Y | -99.8% | 15.4% | 16.6% |
Return vs Industry: GNBT underperformed the US Biotechs industry which returned -28.3% over the past year.
Return vs Market: GNBT underperformed the US Market which returned -20.6% over the past year.
Price Volatility
| GNBT volatility | |
|---|---|
| GNBT Average Weekly Movement | 153.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNBT's share price has been volatile over the past 3 months.
Volatility Over Time: GNBT's weekly volatility has decreased from 242% to 153% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 15 | Joe Moscato | generex.com/index.html |
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer.
Generex Biotechnology Corporation Fundamentals Summary
| GNBT fundamental statistics | |
|---|---|
| Market cap | US$61.03k |
| Earnings (TTM) | -US$37.26m |
| Revenue (TTM) | US$692.76k |
0.1x
P/S Ratio0.0x
P/E RatioIs GNBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNBT income statement (TTM) | |
|---|---|
| Revenue | US$692.76k |
| Cost of Revenue | US$358.60k |
| Gross Profit | US$334.16k |
| Other Expenses | US$37.60m |
| Earnings | -US$37.26m |
Last Reported Earnings
Apr 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 48.24% |
| Net Profit Margin | -5,378.74% |
| Debt/Equity Ratio | -23.7% |
How did GNBT perform over the long term?
See historical performance and comparison